Brown Advisory Inc. Has $4.03 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

Brown Advisory Inc. reduced its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 28.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,860 shares of the biotechnology company's stock after selling 10,426 shares during the quarter. Brown Advisory Inc.'s holdings in Ascendis Pharma A/S were worth $4,031,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ascendis Pharma A/S during the 4th quarter valued at $28,000. Jones Financial Companies Lllp raised its stake in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares during the period. Quarry LP acquired a new stake in Ascendis Pharma A/S during the 4th quarter valued at $96,000. Tower Research Capital LLC TRC grew its holdings in shares of Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after acquiring an additional 664 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Ascendis Pharma A/S during the 4th quarter valued at $174,000.

Ascendis Pharma A/S Trading Down 0.9%

Shares of NASDAQ:ASND opened at $174.96 on Friday. The stock has a market capitalization of $10.70 billion, a PE ratio of -27.86 and a beta of 0.38. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00. The firm has a fifty day moving average price of $168.27 and a 200 day moving average price of $153.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Evercore ISI boosted their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Royal Bank Of Canada boosted their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Cantor Fitzgerald restated an "overweight" rating and set a $200.00 price target on shares of Ascendis Pharma A/S in a report on Monday, May 12th. JPMorgan Chase & Co. boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a report on Friday, May 2nd. Finally, Citigroup boosted their price target on shares of Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a report on Friday. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $223.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.